Glenmark Pharmaceuticals has launched a fixed-dose combination (FDC) of its novel, patent-protected,  globally researched Sodium-Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin (first-line medication for the treatment of type 2 diabetes). The fixed drug combination is indicated for the management of Type 2 diabetes.

The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo MV and Remozen MV.

Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed-dose combination (FDC) and India is the first country to get access to this FDC drug. Glenmark received approval from the DCGI (the drug approval authority in India) for manufacturing and marketing this fixed dose combination in late September 2021.  

Glenmark’s Remogliflozin + Vildagiptin + Metformin combination has been launched at a breakthrough price of Rs. 16.50 per tablet, to be taken twice daily; which amounts to Rs.33.00 as the per-day cost of therapy. This cost is at least 53 per cent lower than the other available SGLT2 & DPP4 combination drugs administered along with Metformin, in India.